Methods for increasing blood oxygen saturation

JP2024541338A5Pending Publication Date: 2024-11-20THERMOLIFE INTERNATIONAL LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024527543
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-08-13
Filing Date
2021-11-12
Publication Date
2024-11-20

AI Technical Summary

Technical Problem

There is a lack of effective and safe treatments for conditions causing abnormally low blood oxygen saturation, such as those experienced by COVID-19 patients and individuals with respiratory diseases like asthma, which can lead to long-term lung damage and other health complications.

Method used

Oral administration of elemental metals, such as magnesium and zinc, combined with nitrate or nitrite ions, and an acid like citric acid, to increase blood oxygen saturation levels by producing nitric oxide gas in the body.

Benefits of technology

The combination effectively raises blood oxygen saturation levels within minutes to hours, alleviating symptoms and preventing long-term damage, without causing methemoglobinemia or other harmful side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure is directed to compositions and methods for increasing oxygen saturation (SpO2) in a subject in need of such an increase, as well as compositions and methods for alleviating, treating or curing symptoms and conditions associated with reduced SpO2 levels (less than 95%). The compositions are preferably solid and include a nitrate anion source, an elemental metal (uncharged), and optionally an acid. The compositions are preferably administered orally. In general, the present disclosure is directed to a method for treating a respiratory disease comprising administering to a subject an effective amount of an elemental metal and administering to a subject an effective amount of a nitrate anion (NO3-) source.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 113,114, filed November 12, 2020; U.S. Provisional Patent Application No. 63 / 148,517, filed February 11, 2021; and U.S. Provisional Patent Application No. 63 / 232,852, filed August 13, 2021, the contents of each of which are incorporated by reference herein in their entirety.

[0002] Technical Field The present invention relates generally to compositions for oral administration and related methods of use for the effective and safe treatment of patients suffering from abnormally low SpO2 levels (e.g., <95%) caused either by a respiratory infection (e.g., Covid-19 infection) or other causes. [Background technology]

[0003] background Acute Respiratory Distress Syndrome (ARDS) occurs when the lungs are severely injured, which can result from infection or trauma. During the onset of ARDS, fluid from the smallest blood vessels in the lungs begins to leak into the alveoli, which makes the lungs smaller and stiffer. The patient finds it harder to breathe, and the amount of oxygen in the blood drops. Once the body is starved of oxygen (hypoxemia), damage to the brain and other tissues can lead to organ failure. ARDS patients need help opening closed air spaces to get oxygen into the blood and make breathing easier. For these reasons, ventilators and extra oxygen are used and maintained until the injury resolves.

[0004] Up to 25% of ARDS survivors develop physiologic evidence of restrictive lung disease within 6 months of ARDS diagnosis. More severe prolonged illness and pulmonary causes of ARDS are thought to be risk factors for progression to fibrosis. Fibrotic lung disease may be a complication of prolonged respiratory failure from ARDS. Pulmonary function test abnormalities in ARDS survivors usually resolve over time. However, up to 25% of patients have persistent restrictive abnormalities 6 months after ARDS diagnosis, and many also have residual imaging abnormalities. These findings may be consistent with fibrosis. Indeed, more severe prolonged illness and pulmonary causes of ARDS are thought to be risk factors for progression to fibrosis.

[0005] Coronavirus disease 2019 (COVID-19) is a contiguous respiratory and vascular disease. Specifically, it is a severe acute respiratory syndrome caused by the novel coronavirus SARS-CoV-2. Common symptoms include fever, cough, fatigue, shortness of breath or difficulty breathing, chest pain, and loss of smell and taste. Another common symptom of COVID-19 is low blood oxygen saturation, with many patients exhibiting oxygen saturation levels below the normal 95%-100% range. Crucially, sick patients exhibit oxygen saturation levels below 50%, which can lead to death due to low oxygenation from the lungs.

[0006] While most people have mild symptoms associated with COVID-19, some develop ARDS (possibly induced by a cytokine storm), multiple organ failure, septic shock, and blood clots. COVID-19 patients who develop ARDS are typically diagnosed by measuring their blood oxygen saturation (SpO2) levels, which are typically below normal levels of 95%-100%. In a hospital setting, the patient's arterial oxygen saturation (SaO2) may also be measured, which directly measures the amount of oxygen gas in the patient's blood from a blood sample. Normal levels of SaO2 are also typically 95%-100%. Medical professionals may use both SpO2 and SaO2 to determine whether a subject is suffering from hypoxia. More long-term damage to organs (especially the lungs and heart) has been observed, and concern exists about the significant number of patients who recover from the acute phase of the disease, but continue to experience a range of effects for several months afterward, including severe fatigue, memory loss and other cognitive problems, low-grade fever, muscle weakness, breathlessness, and other symptoms. Although many COVID-19 patients who develop ARDS survive their SARS-CoV-2 infection, many of them have long-term lung damage with persistent symptoms (e.g., fatigue, inability to exercise, work, or have sex, burnout, weakness, exhaustion, exhaustion, lethargy, collapse, tiredness, or fatigue, worsening of symptoms after physical or mental activity (also known as post-exertional fatigue), difficulty thinking or concentrating (sometimes referred to as "brain fog"), cough, chest or stomach pain, headache, fast or racing heart (also described as palpitations), joint pain, muscle pain, tingling sensations (paresthesias), diarrhea, sleep problems, fever, orthostatic dizziness (lightheadedness), rash, mood swings, changes in smell and taste (anosmia), and changes in menstrual cycle). These symptoms can persist for months after SARS-CoV-2 infection.

[0007] Some people who have had severe illness with COVID-19 experience longer term, multi-organ effects or autoimmune conditions with symptoms that persist for weeks or months after COVID-19 illness. Multi-organ effects can affect many, if not all, body systems, including the heart, lungs, kidneys, skin, and brain function. Autoimmune conditions occur when the human immune system mistakenly attacks healthy cells in the human body, causing inflammation (swelling) or tissue damage in affected body sites.

[0008] Although rare, some people (mostly children) develop multisystem inflammatory syndrome (MIS) during or shortly after SARS-CoV-2 infection. MIS is a condition in which various body parts can become inflamed. MIS can result in a post-COVID state if an individual continues to experience multi-organ effects or other symptoms. These symptoms and diagnoses can persist for several months.

[0009] Previous epidemics caused by coronaviruses are instructive in that 30% of SARS and MERS survivors had persistent radiological abnormalities and 15% had persistent physiological constraints in their lungs. Risk factors for fibrosis were older age and ICU admission. Chinese studies have reported persistent radiological findings and abnormal lung function in COVID-19 survivors at the time of hospital discharge. Pre-COVID-19 studies suggest that post-ARDS fibrosis does not progress. Patients with post-ARDS fibrosis clearly show stable impairment in lung function rather than the progression seen in interstitial lung diseases (e.g., idiopathic pulmonary fibrosis (IPF)). Similarly, studies of post-ARDS fibrosis have not reported acute exacerbations such as those seen in IPF. Proposals to test anti-fibrotic drugs in COVID-19 ARDS are emerging.

[0010] To date, there are no solutions for the successful management, treatment, or cure of COVID-19 patients suffering from long-lasting lung damage. With the emergence of new COVID-19 variants that are resistant or immune to vaccination and the spread of the dominant variants to more geographical areas, the need for prevention, treatment, cure or supportive drugs is greater than ever.

[0011] Respiratory distress, which results in lower than normal oxygen saturation (i.e., SpO2 below 95%), can also occur during severe attacks in people with asthma, which can lead to death. Asthma causes swelling of the airways. This results in narrowing of the airways that carry air from the nose and mouth to the lungs. When allergens or irritants enter the lungs, asthma symptoms are triggered. Symptoms of an asthma attack include difficulty breathing, wheezing, coughing, and chest tightness.

[0012] Today, more Americans than ever before have been diagnosed with asthma (approximately 25 million Americans in 2020). This equates to about 1 in 13 Americans, including 8% of adults and 7% of children. Approximately 20 million U.S. adults age 18 and older have asthma. In adults, asthma is more common in women than men. Asthma is also the number one chronic disease in children. As of 2020, there were approximately 5.1 million children under 18 with asthma. In children, asthma is more common in boys than girls. In 2019, 44.3% of children under 18 with asthma reported having one or more asthma attacks in the past year. Approximately 47.2% of children under 5 with asthma had an episode. Among children ages 5-17, asthma is one of the leading causes of missed school attendance. In 2013, this accounted for over 13.8 million school absences.

[0013] On average, 10 Americans die from asthma each day. In 2019, 3,524 people died from asthma. Many of these deaths are preventable with proper treatment and care. Adults are five times more likely to die from asthma than children. Women are more likely to die from asthma than men, and boys are more likely than girls.

[0014] Race and ethnicity also influence the physical and socioeconomic outcomes associated with asthma. Indeed, asthma frequency, illness, and death are highly associated with poverty, urban air quality, indoor allergens, poor patient education, and inadequate health care. Asthma rates and prevalence of asthma episodes are highest among Black Americans. Black Americans are five times more likely than White Americans to visit an emergency department due to asthma. Black Americans are also nearly three times more likely to die from asthma than White Americans. Among children, Black children are three times more likely to have asthma compared to White children. When gender is considered as a factor, Black women have the highest percentage of deaths attributable to asthma. In 2019, Black women were three times more likely to die from asthma than White men.

[0015] Asthma is one of the most common and costly diseases in the country. In 2016, asthma accounted for 9.8 million doctor's office visits. In 2018, asthma accounted for 178,530 discharges from hospital inpatient care and 1.6 million emergency department visits. From 2008 to 2013, the annual economic cost of asthma was more than $81.9 billion (including medical costs and lost work and schooling: >$3 billion lost work and schooling; >$29 billion lost asthma-related deaths; and >$50.3 billion in medical costs). The annual incremental per capita medical costs of asthma were $3,266 (in 2015 US dollars).

[0016] Asthma can be managed with proper prevention, and attacks can be treated with bronchodilator inhalation, but asthma is not cured.Unfortunately, inhalation does not eliminate the chest discomfort associated with asthma, and both steroid and bronchodilator inhalation have many side effects.Other disadvantages of using inhalation to manage asthma include poor availability, the need for many doses throughout the day, and the inability to carry them as luggage when traveling due to air safety reasons.Therefore, there is a need for alternative methods to cure asthma attack symptoms.

[0017] Other diseases that can result in low oxygen saturation include chronic obstructive pulmonary disease (COPD), mesothelioma, anemia, asthma, blood clots in the lungs (pulmonary embolism), collapsed lungs, congenital heart defects or diseases, fluid in the lungs (pulmonary edema), altitude sickness, interstitial lung disease, medications that reduce breathing rate (e.g., certain narcotics and anesthetics), lung inflammation due to toxic factors (e.g., nitrogen dioxide gas), scarring in the lungs (pulmonary fibrosis), sleep apnea, and pneumonia. Chronic hypoxia (characterized by the occurrence of SpO2 below 95% for a period of weeks to months), which has been experienced by past COVID-19 patients, as well as other diseases and conditions, can result in many other diseases. For example, chronic hypoxia is known to increase blood pressure (see Calbet, "Chronic hypoxia increases blood pressure and noradrenaline spillover in healthy humans", J Physiol. 2003, 551(Pt 1): 379-386). Other conditions caused by chronic hypoxia include, but are not limited to, depression and other mood disorders, fatigue, headache, confusion, high blood pressure (hypertension), pulmonary hypertension, increased heart rate (tachycardia), heart failure, acute respiratory failure, and secondary polycythemia (an abnormally increased number of red blood cells). Thus, treating hypoxia may prevent, treat, or cure any of these conditions. Effective, safe methods of treating patients suffering from hypoxia, preferably in an inpatient or home setting, and at a manageable cost, without the need for complex equipment or specialities (e.g., oral feeding (oral intake) treatment), are sorely lacking and urgently needed in the COVID-19 era. [Prior art documents] [Non-patent literature]

[0018] [Non-Patent Document 1] Calbet, “Chronic hypoxia increases blood pressure and noradrenaline spillover in healthy humans”, J Physiol. 2003, 551(Pt 1): 379-386 Summary of the Invention [Means for solving the problem]

[0019] Abstract In general, the present disclosure provides a method of treating a respiratory condition, the method comprising administering to the subject an effective amount of an elemental metal and administering to the subject an effective amount of nitrate anion (NO 3 - In some aspects, the subject is administered a source of elemental metal and nitrate anion (NO 3 - In some aspects, a composition containing a source of nitrite ions (NO 2 - ) is administered in combination with the nitrate ions or even in place of the nitrite ions. The elemental metal is an alkaline earth metal, an alkali metal, or a transition metal. In some embodiments, the elemental metal is elemental magnesium, elemental calcium, elemental lithium, elemental zinc, or elemental iron. In a preferred embodiment, the elemental metal is metallic (uncharged) magnesium and / or zinc. In some aspects, the nitrate anion source is a salt of nitric acid, such as potassium nitrate, sodium nitrate, or magnesium nitrate. In yet other aspects, the nitrate anion source is a plant-derived nitrate ion source. If a nitrite anion source is also added into the recipe, it can be in the form of various nitrite salts (e.g., sodium nitrite, potassium nitrite, etc.) or even derived from fermented plant nitrates reduced to nitrite ions by nitrate-reducing bacteria. Dilute solutions of nitric acid can also be utilized, but are not preferred due to their corrosive effects, as well as other non-practical concerns, such as the chemical incompatibility of nitric acid and the ability of nitric acid solutions to produce nitrogen dioxide gas. In certain implementations, the composition further comprises an acid.

[0020] In some implementations, and for purposes of illustrating the disclosure, the method includes orally administering to a human subject at least one elemental metal; and administering to the human subject nitrate ions (NO 3 - ), nitrite ion (NO 2 - ), or both, wherein the elemental metal is selected from the group consisting of elemental magnesium, elemental calcium, elemental lithium, elemental zinc, elemental sodium, elemental potassium, elemental beryllium, elemental rubidium, elemental cesium, elemental aluminum, elemental gallium, elemental indium, elemental tin, elemental bismuth, elemental scandium, elemental titanium, elemental vanadium, elemental chromium, elemental manganese, elemental cobalt, elemental manganese, elemental scandium, elemental titanium, elemental nickel, elemental copper, elemental zinc, elemental yttrium, elemental zirconium, elemental niobium, elemental molybdenum, elemental technetium, elemental ruthenium, elemental rhodium, elemental palladium, elemental silver, elemental cadmium, elemental lanthanum, elemental hafnium, elemental tantalum, elemental tungsten, elemental rhenium, elemental osmium, elemental iridium, elemental platinum, elemental gold, and elemental manganese.

[0021] Particular implementations may include one or more or all of the following:

[0022] Further, orally administering to said human subject a pharma- ceutically effective amount of an acid.

[0023] The human subject is administered nitrate and / or nitrite, the human subject is administered citric acid as the acid, the human subject is administered potassium nitrate and / or potassium nitrite.

[0024] The human subject has a blood oxygen saturation level (SpO2 level) of less than about 95% or less than about 92%. The oral administration of the at least one elemental metal and the nitrate ion and / or the nitrate ion to the human subject is repeated within 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 72 hours, or 96 hours of the first oral administration. The human subject is orally administered the at least one elemental metal when the SpO2 level of the human subject falls below about 95% or about 92%.

[0025] The SpO2 level of the human subject is increased by at least about 1% within about 5 minutes to about 2.5 hours after administration of the at least one elemental metal and the nitrate ion and / or the nitrite ion.

[0026] The SpO2 of the human subject is increased to at least about 94% within about 5 minutes to about 2.5 hours after administration of the at least one elemental metal and the nitrate ion and / or the nitrite ion.

[0027] The SpO2 of the human subject is increased to at least about 95% within about 5 minutes to about 2.5 hours after administration of the at least one elemental metal and the nitrate ion and / or the nitrite ion.

[0028] The human subject has coronavirus disease (COVID-19).

[0029] The human subject has hypoxia after recovery from SARS-CoV-2 infection.

[0030] The human subject has a condition selected from the group consisting of SARS-Cov-2 infection, post-coronavirus disease (COVID-19) hypoxia, acute respiratory distress syndrome (ARDS), post-ARDS hypoxia, pneumonia, chronic obstructive pulmonary disease (COPD), mesothelioma, anemia, asthma, pulmonary embolism, lung collapse, congenital heart defect or disease, pulmonary edema, altitude sickness, interstitial lung disease, low respiratory rate, pulmonary inflammation, pulmonary fibrosis, sleep apnea, gastrointestinal infection, Heliobacter pylori infection, and respiratory infection. Wherein the human subject has a viral respiratory infection. Wherein the human subject is hypoxic.

[0031] The human subject exhibits at least one symptom selected from the group consisting of tissue damage, muscle pain, body pain, fatigue, sore throat, shortness of breath, difficulty breathing, chest pain, lung inflammation, cough, fever, loss of smell, loss of taste, sinus congestion, runny nose, decreased blood oxygen saturation, headache, gastrointestinal disorders, nausea, vomiting, diarrhea, fatigue, inability to exercise, work, inability to perform sexual activity, burnout, weakness, exhaustion, exhaustion, listlessness, collapse, tiredness, malaise, worsening symptoms after physical or mental activity, difficulty thinking or concentrating, cough, stomach pain, fast or pounding heartbeat, joint pain, tingling, sleep problems, orthostatic dizziness, rash, mood swings, mood disorders, changes in menstrual cycle, hypertension, depression, increased heart rate, heart failure, and acute respiratory failure, where the tissue damage is in the brain, heart, lungs, and / or kidneys. wherein administration of said at least one elemental metal and said nitrate and / or nitrite ions alleviates said at least one symptom in said human subject.

[0032] The human subject is orally administered a composition comprising the at least one elemental metal and the nitrate ions, the composition comprising from about 1 mg to about 2000 mg of the at least one elemental metal and from about 30 mg to about 4000 mg of the nitrate ions, wherein the composition includes elemental magnesium and / or elemental zinc.

[0033] The human subject is orally administered a composition comprising about 1200 mg potassium nitrate; about 200 mg elemental magnesium; and about 50 mg elemental zinc, wherein the composition further comprises about 1000 mg citric acid, wherein the composition is provided in one or more capsules, wherein the capsules have a size of 0 or smaller, wherein the elemental magnesium metal has a mesh size of 60-200 and the elemental zinc metal has a mesh size of 325 or lower.

[0034] The human subject is administered the nitrite ion, the amount of nitrite ion administered being between about 5 mg and about 300 mg, between about 10 mg and about 200 mg, or between about 30 mg and about 100 mg.

[0035] Oral administration of the nitrite ion does not produce methemoglobinemia in the human subject.

[0036] and orally administering to the human subject at least one gastric acid secretagogue, wherein the at least one gastric acid secretagogue is selected from the group consisting of caffeine, theophylline, theobromine, an ethanol solution, pentagastrin, and a cholinergic agonist, wherein the ethanol solution has 2%-14% ethanol, and wherein the cholinergic agonist is selected from acetylcholine and pilocarpine.

[0037] The human subject is administered a composition comprising the at least one elemental metal and the nitrate ions and / or the nitrite ions, the composition being in a sustained release formulation.

[0038] In some implementations, and for purposes of illustrating the disclosure, the composition for human consumption comprises at least one elemental metal in a mesh size equal to or greater than 35, where the elemental metal is at least one elemental metal selected from the group consisting of elemental magnesium, elemental calcium, elemental zinc, elemental copper, and elemental iron; and nitrate ions (NO 3 - ), nitrite ion (NO 2 - ), or both.

[0039] Particular implementations may include one or more or all of the following:

[0040] The mesh size of the elemental metals is 40 or greater.

[0041] The nitrate ion and the nitrite ion are inorganic salts.

[0042] The composition comprises: from about 1 mg to about 800 mg of the elemental metal; and from about 30 mg to about 2000 mg of the nitrate ions and / or the nitrite ions.

[0043] The at least one elemental metal is elemental magnesium having a mesh size between 60-200.

[0044] The composition is in a dosage form selected from capsules, cachets, pills, tablets, powders, granules, pellets, beads, particles, lozenges, and pastilles. The elemental metal is packaged with the nitrate and / or nitrite ions.

[0045] The composition further comprises an acid, wherein the composition comprises the acid in an amount of about 50 mg to about 20,000 mg, wherein the acid is packaged separately from the elemental metal and the nitrate and / or nitrite ions.

[0046] wherein the elemental metal, the nitrate ion, the nitrate ion, and the acid are in solid form.

[0047] The composition further comprises a gastric acid secretagogue, wherein the gastric acid secretagogue is in an amount sufficient to decrease stomach pH.

[0048] The elemental metal and the nitrate and / or nitrite are in a sustained release formulation. BRIEF DESCRIPTION OF THE DRAWINGS [Brief description of the drawings]

[0049] [Figure 1] FIG. 1 shows the three different forms of elemental magnesium tested in the experiments.

[0050] [Figure 2-1] Figure 2A shows an image at 500x magnification of magnesium powder. Figure 2B shows an image at 500x magnification of magnesium powder reaction with acidified water (1000mg citric acid in 100ml water) for 10 seconds. [Figure 2-2] Same as above.

[0051] [Figure 3-1] Figure 3A shows an image of magnesium granules at 500x magnification. Figure 3B shows an image of magnesium granules at 500x magnification using a micrometer (each notch = 0.1 mm). Figure 3C shows an image of magnesium granules at 500x magnification of reaction with acidified water (1000 mg citric acid in 100 ml water) after 10 seconds. [Figure 3-2] Same as above.

[0052] [Figure 4-1] 4A-4C show a comparison of 500x magnification images of magnesium dust (FIG. 4A), magnesium powder (FIG. 4B), and magnesium granules (FIG. 4C) through a micrometer ruler (each notch is 0.1 mm). [Figure 4-2] Same as above.

[0053] [Figure 5-1]Figure 5A shows magnesium dust at 500x magnification. Figure 5B shows magnesium dust at 500x magnification using a micrometer (each notch = 0.1 mm). Figure 5C shows magnesium dust at 500x magnification reacted with acidified water (1000 mg citric acid in 100 ml water) for 10 seconds. [Figure 5-2] Same as above.

[0054] [Figure 6] FIG. 6A shows the individual changes in oxygen saturation during the study. Each line represents a different patient. FIG. 6B shows the average blood oxygen saturation of the patients during the study. Error bars indicate standard error. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0055] Detailed Description Detailed aspects and applications of the present disclosure are described below in the following Detailed Description of the Technology. Unless specifically noted, the words and phrases in the specification and claims are intended to be given their ordinary, customary, and accustomed meaning to those of ordinary skill in the applicable art.

[0056] In the following description and for the purpose of explanation, many specific details are set forth to provide a thorough understanding of various aspects of the present disclosure. However, it will be understood by those skilled in the relevant art that the implementation of the technology disclosed herein can be carried out without these specific details. It should be noted that there are many different and alternative configurations, devices and technologies to which the technology disclosed herein can be applied. The full scope of the technology disclosed herein is not limited to the examples described below.

[0057] The singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a step" includes reference to one or more of such steps.

[0058] As used herein, the term "about" refers to a deviation of 5% or less from a given value, for example, a deviation of 3%, 2%, 1%, 0.5%, or 0.1% from a given value.

[0059] As referred to herein, "prevention," "prevent," and / or "preventing" are used interchangeably herein and are intended to refer to any process that may slow, interrupt, halt, control, stop the progression of, alleviate symptoms or complications of, or reverse a respiratory disease or disorder.

[0060] As used interchangeably herein, "treatment" and / or "treating" and / or "treat" are intended to refer to any process that may slow, interrupt, halt, control, stop the progression of, alleviate symptoms or complications of, or reverse a respiratory disease or disorder.

[0061] As used herein, the term "acceptable" is a phrase used in its broadest sense and may describe a composition component that meets the Food and Drug Administration (FDA) standard for food-grade substances, the United States Pharmacopeia (USP) standard, the United States Department of Agriculture (USDA) standard, the generally accepted standard of the dietary supplement industry, industry standard, botanical-derived standard, or the standard established by any recognized organization. These standards may delineate the acceptable range of aspects of the composition component, such as the edibility, toxicity, pharmacological effect, or any other aspect of the chemicals, compositions, or preparations used in the implementation of the composition.

[0062] As used herein, the term "composition" refers to both mixtures of ingredients or components, as well as combinations of capsules or tablets containing different ingredients or components. Thus, in certain embodiments, a composition encompasses separate capsules, tablets or other dosage forms that are meant to be packaged together and taken together. For example, the nitrate / nitrite component and the elemental metal component may be in separate capsules, tablets, etc.

[0063] As used herein, the term "elemental metal" refers to the neutrally charged state of a metal element, in other words, a metal in its elemental form and not in a salt or charged form (non-limiting exemplary salt and charged forms include oxides, hydroxides, carbonates, chlorides, lactates, citrates, aspartates, glycinates, and gluconates of the metal). Thus, as used herein, elemental metals and salts of the metals are different entities. For clarity, as used herein, elemental metals (i.e., their uncharged metallic forms) and ionic (charged) forms of the metals (e.g., salts, oxides, and hydroxides) are different entities. The statement that a composition comprises an elemental metal cannot be satisfied by the presence of a metal salt, and vice versa. For example, a composition consisting of magnesium citrate is not a composition comprising elemental magnesium, despite any description that magnesium citrate provides an amount of elemental magnesium. The elemental metals described herein include elemental magnesium, elemental calcium, elemental lithium, elemental zinc, elemental sodium, elemental potassium, elemental beryllium, elemental rubidium, elemental cesium, elemental aluminum, elemental gallium, elemental indium, elemental tin, elemental bismuth, elemental scandium, elemental titanium, elemental vanadium, elemental chromium, elemental manganese, elemental cobalt, elemental manganese, elemental scandium, elemental titanium, elemental copper, elemental zinc, elemental yttrium, elemental zirconium, elemental niobium, elemental molybdenum, elemental technetium, elemental ruthenium, elemental rhodium, elemental palladium, elemental silver, elemental cadmium, elemental lanthanum, elemental hafnium, elemental tantalum, elemental tungsten, elemental rhenium, elemental osmium, elemental iridium, elemental platinum, elemental gold, elemental manganese, and elemental iron.In the composition preferred for treating respiratory ailments, the elemental metal is selected from the group of elemental metal magnesium and elemental metal zinc.

[0064] In some aspects, the present disclosure provides a method for producing a nitrate anion (NO 3 - The present invention relates to the discovery that the oral administration of nitrate anion (NO) sources and elemental metals to subjects with respiratory illness can reduce or alleviate symptoms associated with the respiratory illness. 3 - The researchers surprisingly discovered that administration of potassium nitrate (KNO ) and elemental metals alleviated the subject's symptoms of chest pain, fever, muscle pain, cough, dyspnea, and shortness of breath. In one run, the subject was administered potassium nitrate (KNO ) while experiencing low blood oxygen saturation (between 90-92%). 3 ), elemental magnesium, and elemental zinc. Within 30 minutes of taking the capsule, the subject reported a significant reduction in shortness of breath, chest pain, and difficulty in breathing. The blood oxygen saturation level also increased to 97% within 30 minutes. The effect on blood oxygen saturation was reduced 4 hours after taking the capsule, but administration of a second capsule restored the subject's oxygen saturation level to normal (between 97% and 100%). In some embodiments, administration of a nitrate anion source and elemental metals to a subject with a respiratory illness may accelerate recovery from the respiratory illness.

[0065] These results were quite surprising as previous experiments utilizing nitrate alone at 409mg and 479mg doses did not produce any increase in oxygen saturation (Rosetti et al., "Dietary nitrate supplementation increases acute mountain sickness severity and sense of effort during hypoxic exercise", J Appl Physiol (1985), 2017, 123(4): 983-992, Barlow et al., "The effect of a dietary nitrate supplementation in the form of a single shot of beetroot juice on static and dynamic apnea performance" J Sport Nutr Exerc Metab, 2018, 28(5): 497-501). It was also discovered that the combination of elemental metal and a nitrate anion source could rapidly generate nitric oxide gas and increase pulmonary excretion of nitric oxide. Administration of this combination was effective in increasing leg press weight and time to exhaustion within minutes. Subjects who tested the combination also reported that they felt they could breathe easier during physical activity. Thus, administration of the combination of elemental metal and nitrate anion source provides relief to subjects suffering from low oxygen saturation levels, dyspnea, chest pain, and shortness of breath.

[0066] The present disclosure relates to the discovery that the mesh size of elemental metals used to generate nitric oxide (NO) affects the therapeutic effectiveness of the NO generated when combined with acid and nitrate anions in solution and administered to a subject in need of NO therapy.

[0067] The term "mesh" describes the size of the abrasive particle. When a mesh size (or grade) of particle is reported, it reports the mean or average diameter of the particles in that mesh size or grade. When two numbers are used in referring to the mesh size of a particle, this indicates that all of the particles in that grade of product are within that mesh size range (i.e., mesh size 80-100).

[0068] US mesh size (or US sieve size) is defined as the number of openings per square inch of a screen. For example, a size 36 mesh screen has 36 openings, while a size 150 mesh screen has 150 openings. Since the size of the screen (per square inch) is constant, a higher mesh number refers to smaller screen openings and therefore smaller particles. Generally, US mesh sizes are measured using screens up to size 325 mesh (325 openings per square inch). Sometimes the mesh size of a product is noted with either a minus (-) or plus (+) sign. These signs indicate that the particles are either all smaller (-) or all larger (+) than that mesh size. For example, a product specified as -100 mesh contains only particles that passed through a 100 mesh screen. The +100 grade contains particles that did not pass through a 100 mesh screen. When the grade of a product is noted with a dash or slash, it indicates that the product has particles that fall within the two mesh sizes. For example, a 30 / 70 or 30-70 grade only has particles smaller than 30 mesh and larger than 70 mesh.

[0069] Table 1 shows a mesh conversion chart. It gives the approximate sizes in inches and microns for various mesh sizes. These values ​​are generally accepted as accurate, but are approximations because the thickness of the wire used to make a particular screen will vary the number of openings per square inch. Most grades below 325 mesh are given in micron sizes because these sizes are not manufactured using screens. Table 1. Mesh conversion chart

Table 1

[0070] Elemental metals with mesh sizes greater than and equal to 35 or less than 325 mesh size are soluble in at least one elemental metal and nitrate anion (NO 3 - ) or nitrite anion (NO 2 - It has been surprisingly discovered that the most therapeutic effect is produced while limiting the amount of side effects experienced (e.g., gastrointestinal upset, nausea, vomiting, heartburn) following administration of a composition comprising a source of elemental metal and nitrate and / or nitrite. Depending on the metal and its reactivity with the nitrate or nitrite ions and acid, different mesh sizes may be preferred, but generally, mesh sizes of 40-325 produce better therapeutic effects for magnesium and zinc, with the optimum mesh size for magnesium being 60-200 (commonly referred to as magnesium metal powder) and for zinc being 325 or larger (commonly referred to as zinc dust). In some aspects, administering a composition of elemental metal and nitrate and / or nitrite ions comprises orally administering to the subject at least one elemental metal having a mesh size of 35 or larger, and orally administering to the subject a source of nitrate and / or nitrite anions. In some other aspects, administering the composition includes orally administering to the subject at least one elemental metal having a mesh size of 35 or larger, and orally administering to the subject a source of nitrate and / or nitrite anions and an acid (e.g., citric acid), the acid being preferably in a separate dosage form (such as a capsule, powder, or tablet). Administration of a composition of elemental metal and nitrate or nitrite anions, or a composition of elemental metal and nitrate and / or nitrite anions and an acid (e.g., citric acid) improved alertness, energy levels, cured headaches / migraines, increased athletic performance as indicated by increased muscle strength and endurance, and reduced symptoms of respiratory ailments (e.g., shortness of breath, breathing problems, chest pain, lung inflammation, and / or decreased oxygen saturation) in a shorter period of time following administration than administration of a composition not having the elemental metal having a mesh size between 40-325. Subjects also experienced greater relief from respiratory symptoms when administered a composition of elemental metal and nitrate or nitrite anion, or a composition of elemental metal and nitrate or nitrite anion and acid (e.g., citric acid), where the elemental metal has a mesh size between 40 and 200.In some embodiments, gastrointestinal side effects (e.g., gastrointestinal upset, diarrhea, nausea, heartburn, and vomiting) associated with ingestion of the composition were reduced when the composition included an elemental metal having a mesh size greater than 35.

[0071] In some implementations, the nitrate / nitrite component and the elemental metal component are in separate capsules, tablets, etc. as oral dosage forms.

[0072] Other methods that the inventors have discovered that may prevent the occurrence of side effects include: - taking said capsule with a sufficient amount of water, preferably cold (below room temperature), in a volume of at least 500 ml; - avoid taking the capsules in a fasted state (no food in the stomach, usually achieved by abstaining from food intake for at least 8 hours); and - Consumption of milk or other neutral to alkaline products in case of extreme discomfort after taking the preparation.

[0073] As shown in the examples, under the acidic conditions that can be safely achieved in the human stomach, granular magnesium reacts too slowly and produces too little NO to achieve a discernible / observable therapeutic effect. Although the mechanism by which NO gas can have a systemic effect on the body or reach the lungs is not known, the inventors have observed that reduced NO gas production in the stomach correlates with reduced or no therapeutic effect of the ingested formulation. There is also concern that low mesh granular magnesium may not be able to react sufficiently before leaving the stomach and being wasted. To prove this, the inventors added 200 mg of granular (mesh size 35) elemental metallic magnesium with 200 mg of elemental metallic granular magnesium and 1000 mg of citric acid in simulated gastric acid fluid (100 ml of 0.1 N HCl in water). Under normal stomach emptying conditions, less than 60% of the ingested compound / meal was present in the stomach at 2 hours and less than 10% at 4 hours (Banks KP, Syed K, Parekh M, et al., Gastric Emptying Scan. [Updated 2020 Dec 22]. In: StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https: / / www.ncbi.nlm.nih.gov / books / NBK531503 / ). After another 4 hours, granules of elemental magnesium metal were found dotting the bottom of the beaker. On the other hand, the magnesium dust reacted too quickly with the nitrates and acids of the formulation, producing too much NO (itself toxic at 100+ ppm), which also oxidized rapidly to produce highly toxic and potentially lethal NO. 2 Experiments with magnesium dust have shown that there are significant amounts of NO and NO 2 This resulted in the generated gas reaching both gas sensors at the maximum toxic levels in the chamber (250 ppm NO and 100 ppm NO) in less than one minute. 2 ). The solution also rapidly gained heat (the 100 ml solution reached over 80°C from an ambient temperature of 30°C), which would have caused damage and burns to tissues such as the gastric epithelium. Thus, the magnesium dust is completely toxic to any human and therapeutic use in these quantities would have been inappropriate. On the other hand, magnesium powder (mesh size 60-200) produced NO for a sustained period of over an hour, and NO 2 A maximum concentration of 39.8 ppm NO was achieved with zero production of NO. This is a novel scientific breakthrough, unheard of for a therapeutic agent. Zinc is less reactive than magnesium and can be used at a dust mesh size (325 mesh) to produce NO sustained for over 4 hours (which is one of the recommended intervals between doses of the therapeutic composition of the present disclosure).

[0074] Thus, disclosed herein are compositions comprising an elemental metal having a mesh size greater than 35 and a nitrate or nitrite anion source. In some aspects, the mesh size of the elemental metal is also less than 200. For example, in certain embodiments, the composition comprises an elemental metal having a mesh size between 40 and 200 and the nitrate or nitrite anion source. In some implementations, the nitrate or nitrite anion source is a nitrate or nitrite salt (e.g., potassium nitrate, sodium nitrate, amino acid nitrate, potassium nitrite, amino acid nitrite, or sodium nitrate). In other implementations, the nitrate or nitrite anion source is a plant-derived source, such as a beet root extract or an amaranth extract.

[0075] Disclosed herein is a method for treating a respiratory condition, comprising administering to the subject an effective amount of an elemental metal and administering to the subject an effective amount of a nitrate source. In some implementations, the subject is administered a composition comprising an elemental metal and a nitrate source. In some embodiments, the subject is also administered an acid. The acid is administered to ensure that the stomach pH remains acidic upon ingestion of the claimed composition. In some implementations, the acid is administered in a composition separate from the elemental metal and the nitrate source. Thus, in some implementations, the subject is administered a first composition comprising the elemental metal and the nitrate source and a second composition comprising the acid. Thus, the subject is administered a treatment regimen comprising a dosage form (e.g., capsule, tablet, or pill) comprising the elemental metal and the nitrate source and another dosage form (e.g., in a solid form such as a capsule, tablet, or pill, or in a liquid form) comprising the acid. In other implementations, the elemental metal, the nitrate source, and the acid are administered in a dosage form (e.g., a capsule or tablet) that includes the three components. In certain embodiments, instead of administering a nitrate source, a nitrite source is administered. In other embodiments, the subject is administered both a nitrate source and a nitrite source.

[0076] In certain implementations, the subject exhibits at least one symptom selected from the group consisting of shortness of breath, breathing problems, chest pain, lung inflammation, and decreased oxygen saturation. In some aspects, the subject has a respiratory infection. In some cases, the subject has a viral infection and / or a bacterial infection. For example, an infection with coronavirus, influenza virus, respiratory syncytial virus, Streptococcus pneumoniae, Haemophilus influenzae type b (Hib), and / or Pneumocystis jiroveci. In some implementations, the subject is diagnosed with pneumonia or severe acute respiratory syndrome caused by a coronavirus (e.g., an alphacoronavirus selected from 299E and NL63 or a betacoronavirus selected from OC43, HKU1, MERS-CoV, SARS-CoV, or SARS-CoV-2). In some aspects, administration of an effective amount of an elemental metal and an effective amount of a nitrate anion source reduces symptoms of shortness of breath, breathing problems, chest pain, lung inflammation, and / or decreased oxygen saturation in the subject. In certain implementations, the elemental metal and the nitrate anion source are administered to the subject every four hours. In some aspects, repeated administration continues until at least one of the symptoms is eliminated, for example, for at least two or four days.

[0077] In other aspects, the subject has a respiratory fungal infection, such as aspergillosis. In some aspects, the subject has a protozoan respiratory infection and symptoms, such as direct damage to parenchymal tissue (e.g., toxoplasmosis); via a systemic inflammatory response with hematogenous dissemination (e.g., malaria); and contact with adjacent lesions (e.g., amebiasis). In some aspects, the subject has lung inflammation caused by toxic agents (e.g., nitrogen dioxide). In some aspects, the subject may have lung inflammation and subsequent breathing problems of unknown cause.

[0078] In certain implementations, the subject exhibits at least a symptom selected from the group consisting of shortness of breath, breathing problems, chest pain, lung inflammation, and decreased oxygen saturation. In some aspects, the subject has a respiratory infection. For example, an infection with coronavirus, influenza virus, respiratory syncytial virus, Streptococcus pneumoniae, Haemophilus influenzae type b (Hib), and / or Pneumocystis jiroveci. In some implementations, the subject is diagnosed with severe acute respiratory syndrome caused by a coronavirus, for example, an alphacoronavirus selected from 299E and NL63, or a betacoronavirus selected from OC43, HKU1, MERS-CoV, SARS-CoV, or SARS-CoV-2. In some aspects, administration of an effective amount of an elemental metal and an effective amount of a nitrate or nitrite anion source reduces symptoms of shortness of breath, breathing problems, chest pain, lung inflammation, and / or decreased oxygen saturation in the subject. In certain implementations, the elemental metal and nitrate or nitrite anion source are administered to the subject every 4 hours. The frequency of administration depends on the potency of the dose, but for example, the frequency and / or amount of the dose may be altered depending on the progression of the disease and the severity of symptoms, or as directed by a supervising medical professional. For example, patients with early onset COVID-19 and mild symptoms (SpO2 between 93-94) may require half the dose, or may be administered every 4 hours or every 8 hours. Severe COVID-19 cases that have progressed to extensive lung damage (SpO2 below 85) may require double the dose, or may require administration every 2 hours, or even more. In some aspects, repeated administration continues until at least one of the symptoms is eliminated, for example, for at least 2 or 4 days, or longer.

[0079] Also disclosed are methods of increasing blood oxygen saturation levels in a subject; reducing coughing in a subject; reducing migraines and headaches in a subject; reducing gastrointestinal disorders in a subject (e.g., diarrhea, nausea and / or vomiting, Helicobacter pylori infection, ulcers, or irritable bowel syndrome); reducing fever in a subject; reducing shortness of breath or difficulty in breathing in a subject; reducing muscle and body pain in a subject; reducing loss of smell and taste in a subject; reducing sore throat in a subject; reducing congestion or runny nose in a subject; reducing fatigue in a subject; reducing chest pain in a subject; and reducing organ damage caused by low blood oxygen levels in a subject.

[0080] The elemental metals are alkaline earth metals, alkali metals, or transition metals. Because elemental metals are reactive, they are not found in nature. Rather, they exist as ores that contain mixtures of various metal compounds (e.g., salts and oxides). Thus, complex extraction and purification using physicochemical methods are required to produce elemental metals. In some embodiments, the elemental metal is elemental magnesium, elemental calcium, elemental lithium, elemental zinc, elemental sodium, elemental potassium, elemental beryllium, elemental rubidium, elemental cesium, elemental aluminum, elemental gallium, elemental indium, elemental tin, elemental bismuth, elemental scandium, elemental titanium, elemental vanadium, elemental chromium, elemental manganese, elemental cobalt, elemental manganese, elemental scandium, elemental titanium, elemental copper, elemental zinc, elemental yttrium, elemental zirconium, elemental niobium, elemental molybdenum, elemental technetium, elemental ruthenium, elemental rhodium, elemental palladium, elemental silver, elemental cadmium, elemental lanthanum, elemental hafnium, elemental tantalum, elemental tungsten, elemental rhenium, elemental osmium, elemental iridium, elemental platinum, elemental gold, elemental manganese or elemental iron. In some embodiments, the elemental metal is selected from the group consisting of elemental magnesium, elemental calcium, elemental lithium, elemental zinc, and elemental iron. In some embodiments, the subject is administered a combination of elemental metals. Thus, in some aspects, the composition administered to the subject includes more than one elemental metal. The elemental metal can be in any form, such as a powder or granules, or any other form in which the metal remains uncharged prior to combining with the nitrate ion and the acid.

[0081] In some aspects, the nitrate anion (NO 3 - ) is an amino acid nitrate or amino acid or amino acid derivative (e.g., creatine nitrate, arginine nitrate, carnitine nitrate, n-acetylcarnitine nitrate, citrulline nitrate, betaine nitrate, and proline nitrate), inorganic nitrate (e.g., magnesium nitrate, sodium nitrate, potassium nitrate, calcium nitrate, and lithium nitrate), or other mixed salts, co-crystal preparations, and hydrates), or a natural nitrate source. With respect to a natural nitrate source, the nitrate is concentrated and / or isolated from a natural source (e.g., a plant-derived nitrate source). Examples of natural nitrate sources include, but are not limited to, beet juice, beet juice powder, concentrated beet juice powder, celery powder, spinach and red spinach leaf extract, and amaranth extract. In a preferred implementation, the nitrate content of the natural nitrate source is standardized to provide a sufficient amount of nitrate. In some aspects, the composition includes more than one nitrate anion source.

[0082] In some aspects, the nitrite anion (NO 2 - ) is a salt of an amino acid nitrite or an amino acid derivative (e.g., creatinine nitrite, arginine nitrite, carnitine nitrite, n-acetylcarnitine nitrite, citrulline nitrite, betaine nitrite, and proline nitrite), an inorganic nitrite (e.g., magnesium nitrite, sodium nitrite, potassium nitrite, calcium nitrite, and lithium nitrite, or mixed salts, co-crystal preparations, and hydrates thereof), or a natural source of nitrite ion. With respect to natural sources of nitrite ion, the nitrite ion is concentrated and / or isolated from a natural source (e.g., a plant-derived nitrite ion source).

[0083] In some embodiments, the elemental metal and nitrate and / or nitrite anions are included in a system for sustained release of NO.For example, the system can be a time-release system (e.g., diffusion system, dissolution system, osmotic pressure system, and ion exchange resin, or any other effective time-release system), a floating system, a bioadhesive system, or a matrix system in which exposure to the acid or acid solution is controlled.In other implementations, either mechanical or electrical methods can be utilized to release the metal and nitrate or nitrite anions into the acid solution in a continuous manner that allows sustained NO gas release.

[0084] In some implementations, the method includes providing the acid in powder form mixed with the nitrate or nitrite anions and / or the elemental metal before dissolving in a solvent to generate NO gas. The acid in powder form can be, for example, citric acid, malic acid, or fumaric acid. In a preferred embodiment, the solvent used is water because it is safe, non-toxic, and readily available. However, other protic and / or polar solvents can be utilized (e.g., ammonia, ethanol, acetic acid, etc.). The water or solvent need not be pure, and other compounds can be dissolved therein (e.g., fragrances, scents, other medicines, etc.). In some embodiments, the acid is a salt of a strong acid and a weak base, which when dissolved in water or some other polar protic solvent results in the formation of an acidic solution. Thus, the acid can be ammonium chloride, ammonium nitrate, or creatine nitrate. In certain implementations, when the nitrate or nitrite anion is provided as a nitrate or nitrite salt formed with a weak base (e.g., creatine or proline), the nitrate or nitrite salt can serve as a source of both the acid and the nitrate or nitrite anion.

[0085] The usual order of adding ingredients of the formula is to first make an acid solution and then add the elemental metal and the nitrate or nitrite ions simultaneously, although it is understood that there can be various variations. For example, combining nitrate or nitrite anions and elemental metal in an acid solution can include adding the nitrate or nitrite ions, the dispersible acid, and the elemental metal simultaneously in water, or preparing a solution of nitrate ions in water and then adding the acid and elemental metal. An important feature of the method of the present disclosure is that the elemental metal cannot be allowed to react completely with the acid before being combined with the nitrate ions. Otherwise, the elemental metal and the acid will form a salt of the elemental metal and will not produce NO gas. Thus, if one were to add elemental magnesium in an acid solution, adding nitrate or nitrite anions after the reaction is complete (as indicated by the dissolution of magnesium in its salt form in the liquid) will not form nitric oxide gas.

[0086] Methemoglobinemia, a condition that can be monitored by reduced SpO2 levels, is a side effect associated with conventional inhaled NO therapy (Raut and Maheshwari, "Inhaled nitric oxide, methemoglobinemia, and route of delivery." Saudi J Anaesth. 2017, 11(3):364). It has been surprisingly found that administration of NO gas according to the methods described herein does not result in the development of methemoglobinemia. The mechanism as to why methemoglobinemia was not caused by the methods of the present disclosure is still under investigation, but it is suspected that the hydrogen gas product of the reaction of the nitrate or nitrite anion and elemental metals in the acidic solution may have a protective effect. Prevention and treatment of methemoglobinemia is a result of the present invention, and there are additional elemental metals that can generate hydrogen by reacting with base (e.g., aluminum: 2Al + 2NaOH + 2H 2 O → 2NaAlO 2 It should be noted that for purposes of the present invention, NO gas can be produced by the reaction of nitrite or nitrate ions with an acid in one beaker, and H by the reaction of a metal (e.g., aluminum) in contact with a base to produce hydrogen in another beaker. 2 Gas may be produced.

[0087] During the experimental and development stages of this invention, one of the inventors found himself exposed on multiple occasions to NO levels above 25 ppm (as measured by a BW BWS-NY yellow housing, Solo nitric oxide (NO) gas detector) with no adverse effects observed. Indeed, SpO 2 The inventor's oxygenation levels as measured by oximeter were consistently in the range of 97-100. Thus, also disclosed herein is a method for preventing the development of methemoglobinemia from exposure to nitrate, nitrite, or NO, the method comprising administering hydrogen to the subject exposed to a nitrate source, a nitrite source, or NO.

[0088] In some embodiments, the amount of elemental metal and the amount of nitrate or nitrite anion source administered are between about 1 mg and about 2000 mg, and between about 4 mg and about 4000 mg, respectively. In certain embodiments, the subject is administered about 1 to about 900 mg elemental magnesium and an amount of a nitrate or nitrite anion source providing about 5 to about 2000 mg nitrate or nitrite anion, about 30 mg to about 4000 mg nitrate or nitrite anion, or about 50 mg to about 4000 mg nitrate or nitrite anion. In some aspects, the nitrate or nitrite anion source provides from about 30 mg to 2000 mg of nitrate or nitrite anion, from about 50 mg to about 2000 mg of nitrate or nitrite anion, from about 5 mg to about 1000 mg of nitrate or nitrite anion, from about 30 mg to about 1000 mg of nitrate or nitrite anion, from about 50 mg to about 1000 mg of nitrate or nitrite anion, from about 5 mg to about 600 mg of nitrate or nitrite anion, from about 30 mg to about 600 mg of nitrate or nitrite anion, from about 50 mg to about 600 mg of nitrate or nitrite anion, from about 5 mg to about 500 mg of nitrate or nitrite anion, from about 30 mg to about 500 mg of nitrate or nitrite anion, or from about 50 mg to about 500 mg of nitrate or nitrite anion.

[0089] In some aspects, the molar ratio of the nitrate or nitrite anion source to the elemental metal administered to the subject is at least 2:1. The dose of the elemental metal and the nitrate or nitrite anion source may be adjusted according to the weight, age, and health of the subject. In some embodiments, the amount of elemental metal in the composition is between 1 mg and 800 mg, or between 5 mg and 400 mg. In some embodiments, the amount of nitrate or nitrite anion source is between 30 mg and 2000 mg, or between 50 mg and 600 mg. In one embodiment, the composition comprises 100 mg of elemental metal and 250 mg of magnesium nitrate hexahydrate (equivalent to 60.5 mg of nitrate anion and 23.6 mg of Mg).

[0090] The acid is administered with the elemental metal and a nitrate or nitrite anion source to ensure that the stomach pH remains acidic upon ingestion of the claimed composition. The acid component can be any acid suitable for human consumption. Non-limiting examples include citric acid, succinic acid, malic acid, ascorbic acid, or tartaric acid or any gastric acid-inducing secretagogue. In some aspects, the acid is in a solid form, such as a powder. Thus, the amount of acid in the composition is, in some embodiments, between 50mg and 20,000mg, between 50mg and 2000mg, between 50mg and 1000mg, between 100mg and 20,000mg, between 100mg and 2000mg, between 100mg and 1000mg, between 200mg and 20,000mg, between 200mg and 2000mg, between 200mg and 1000mg, between 300mg and 20,000mg, between 300mg and 2000mg, between 300mg and 1000mg, between 500mg and 20,000mg, between 500mg and 2000mg, or between 500mg and 1000mg. In some aspects, the acid component of the composition is vinegar. In some implementations, the compositions of the present disclosure do not include acid, but the compositions are administered with an acid or a gastric acid-inducing secretagogue. For example, the composition is co-administered with an acidic solution having a pH between 2 and 6, such as a solution of dilute vinegar or citric acid. In some aspects, the acidic solution is dilute acetic acid, nitric acid, sulfuric acid, or the like.

[0091] When the subject is administered a composition comprising an elemental metal and a nitrate or nitrite source, the composition comprises an effective amount of the nitrate or nitrite source and an effective amount of the elemental metal. The effective amount of the elemental metal enhances the effectiveness of the nitrate or nitrite in providing a beneficial effect. Thus, in some embodiments, the effective amount of the nitrate or nitrite source is sufficient to restore oxygen saturation levels in a subject with low oxygen saturation.

[0092] In certain embodiments, the composition comprises 1 to about 900 mg elemental magnesium and a nitrate or nitrite source providing from about 5 to about 2000 mg nitrate or nitrite anion, from about 30 mg to about 4000 mg nitrate or nitrite anion, or from about 50 mg to about 4000 mg nitrate or nitrite anion. In some aspects, the nitrate or nitrite anion source provides about 30 mg to 2000 mg of nitrate or nitrite anion, about 50 mg to about 2000 mg of nitrate or nitrite anion, about 5 mg to about 1000 mg of nitrate or nitrite anion, about 30 mg to about 1000 mg of nitrate or nitrite anion, about 50 mg to about 1000 mg of nitrate or nitrite anion, about 5 mg to about 600 mg of nitrate or nitrite anion, about 30 mg to about 600 mg of nitrate or nitrite anion, about 50 mg to about 600 mg of nitrate or nitrite anion, about 5 mg to about 500 mg of nitrate or nitrite anion, about 30 mg to about 500 mg of nitrate or nitrite anion, or about 50 mg to about 500 mg of nitrate or nitrite anion.

[0093] In some aspects, the molar ratio of the nitrate or nitrite anion source to the elemental metal in the composition is at least 2:1. The dose of the elemental metal and the nitrate or nitrite anion source may be adjusted according to the weight, age, and health of the subject. Typically, a normotensive subject will require less elemental metal and nitrate or nitrite anion than a hypertensive subject, and a hypotensive subject will require even less elemental metal and nitrate or nitrite anion than a normotensive subject. In some embodiments, the amount of elemental metal in the composition is between 1 mg and 800 mg, or between 5 mg and 400 mg. In some embodiments, the amount of nitrate or nitrite anion source is between 30 mg and 2000 mg, or between 50 mg and 600 mg. In one embodiment, the composition comprises 100 mg of elemental metal and 250 mg of magnesium nitrate hexahydrate (60.5 mg of nitrate anion (NO 3 - ) and 23.6 mg Mg equivalent.

[0094] In some embodiments, the elemental metal in the composition is coated or microencapsulated with a suitable material that is poorly soluble in water but soluble in the acidic environment of the stomach (e.g., magnesium oxide, cellulose polymers, alginates (e.g., calcium alginate), or aluminum hydroxide).

[0095] In certain embodiments, proline nitrate or proline nitrite is the source of nitrate or nitrite anions in the composition. In some embodiments, the magnesium nitrate or magnesium nitrite is the source of nitrate or nitrite anions in the composition. In such embodiments, the magnesium nitrate or magnesium nitrite may be anhydrous or hydrated. The degree of hydration of magnesium nitrate or magnesium nitrite is between 1-6 molecules of water per molecule of magnesium or nitrite ion. In certain embodiments, magnesium nitrate hexahydrate is the nitrate salt in the composition.

[0096] In some embodiments, the composition of the present disclosure further comprises an acid. The acid component can be any acid suitable for human consumption, such as citric acid, succinic acid, malic acid, ascorbic acid, or tartaric acid. In some aspects, the acid is in a solid form, such as a powder. Thus, the amount of acid in the composition is, in some embodiments, between 50mg and 20,000mg, between 50mg and 2000mg, between 50mg and 1000mg, between 100mg and 20,000mg, between 100mg and 2000mg, between 100mg and 1000mg, between 200mg and 20,000mg, between 200mg and 2000mg, between 200mg and 1000mg, between 300mg and 20,000mg, between 300mg and 2000mg, between 300mg and 1000mg, between 500mg and 20,000mg, between 500mg and 2000mg, or between 500mg and 1000mg. In some aspects, the acid component of the composition is vinegar. In some implementations, the compositions of the present disclosure do not include an acid, but the compositions are administered with an acid. For example, the composition is co-administered with an acidic solution having a pH between 2 and 6, such as a solution of dilute vinegar or citric acid. In some aspects, the acidic solution is dilute acetic acid, nitric acid, sulfuric acid, etc. In some embodiments for patients who cannot consume production substances due to health reasons (e.g., patients with gastric ulcers and GERD), the acid component can be replaced with gastric acid secretagogues (compounds that stimulate the excretion of gastric acid in the stomach) such as caffeine, bitter compounds, ethanol (preferably at a concentration of 2-14%), or even drugs such as pentagastrin or cholinergic agonists such as acetylcholine and pilocarpine.

[0097] The composition of the present disclosure may be in the form of capsules, tablets, pills, liquids, liquid suspensions, vapors, powders, granules, pulverulence, or combinations thereof. In preferred embodiments, the composition of the present disclosure is in solid form. In some embodiments, the elemental metal and the nitrate or nitrite anion source, and in some aspects, the acid, are combined into a capsule or tablet. In other embodiments, the acid is in a separate tablet or capsule from the elemental metal and the nitrate or nitrite ion source. The enhanced activity of the co-administration of the nitrate or nitrite anion source and the elemental metal is not reduced when the subject takes the nitrate or nitrite anion source and the elemental metal separately at different times (e.g., via co-administration of separate capsules of the nitrate or nitrite anion source and the elemental metal). Thus, in some aspects, the composition described herein comprises a capsule containing a nitrate or nitrite anion source and a capsule containing an elemental metal. In embodiments of the composition further comprising an acid, the composition further comprises a capsule comprising the acid.

[0098] It is worth noting that the powdered form of the composition of the present disclosure loses its efficacy when all the components are combined and completely reacted in water before ingestion. Thus, care should be taken to minimize exposure to water when administering the powdered form of the composition before immediate administration. For example, instead of dissolving the powdered composition in water and drinking the mixture, the subject should ingest the powdered composition and then wash it down with water. Also, if the composition is added into an alkaline mixture (pH above 7) (e.g., water mixed with baking soda), it can retain its efficacy for at least 10 minutes before ingestion.

[0099] In a preferred embodiment utilized for the treatment of COVID-19 and other respiratory and cardiovascular diseases, the formulation contains 1200 mg KNO 3 FCC grade, a US size 000 gelatin capsule containing 200 mg elemental magnesium metal powder (mesh size 60-200), 50 mg elemental zinc metal dust (mesh size approximately 325), and a separate US size 000 capsule containing 1000 mg anhydrous citric acid (food grade). 3 FCC grade, contained in two US size 0 capsules containing 100 mg elemental magnesium metal powder (mesh size 60-200), 25 mg elemental zinc metal dust (mesh size approximately 325), and two capsules (each food grade) containing 500 mg anhydrous citric acid. In certain cases, administration of the smaller size capsules may help prevent some of the side effects (e.g., gastrointestinal discomfort, nausea, and vomiting) experienced by some patients. Subjects may, for example, receive two 000 capsules (i.e., 1200 mg KNO 3 + 1 capsule containing 200mg elemental magnesium metal + 50mg elemental zinc capsule (referred to herein as "SpO2max") and a second capsule containing citric acid (CA). However, if the subject is experiencing stomach discomfort, the subject may instead swallow two size 0 capsules at half the dose but twice as frequently.

[0100] In one implementation of the method for treating respiratory ailments, the subject receives 100 mg to 250 mg of elemental metal, 250 mg of magnesium nitrate hexahydrate (60.5 mg of nitrate anion (NO 3 - ) and 23.6 mg Mg + In another implementation, the subject is orally administered one capsule containing 1-2 g of amaranth (providing 10-90% nitrate ions), 50-1000 mg vitamin C, 50-1000 mg magnesium oxide, 10-1000 mg L-cysteine, 50-1000 mg theanine, 5-100 mg elemental zinc, 0.5-30 mg folic acid / 5-MTHF, and 1-500 mcg potassium molybdate.

[0101] In another implementation, the subject is administered three capsules, where two of the capsules each contain a nitrate or nitrite source and the elemental metal, while the remaining capsule contains the acid. For example, the capsule containing the nitrate or nitrite source and the elemental metal contains proline nitrate or proline nitrite and elemental magnesium, while the capsule containing the acid contains citric acid. In certain embodiments, the composition includes two capsules, each containing 250-750 mg proline nitrate and 5-200 mg elemental magnesium, and one capsule containing 250-1250 mg citric acid. As another example, the composition includes a plurality of capsules that, when combined, provide 1-2g amaranth (providing 10-90% nitrate ions), 50-1000mg vitamin C, 50-1000mg magnesium oxide, 10-1000mg L-cysteine, 50-1000mg theanine, 5-100mg elemental zinc, 0.5-30mg folic acid / 5-MTHF, and 1-500mcg potassium molybdate. In a preferred implementation, the vitamin C is in a capsule separate from the other components.

[0102] In some aspects, the composition further comprises a suitable pharma- ceutically acceptable coating and / or additive to prevent moisture from entering the tablet. Non-limiting examples of the pharma-ceutically acceptable coating include wax, polymer, solid fatty acid, etc. Non-limiting examples of the additive include carriers, excipients, binders, colorants, flavorings, preservatives, buffers, diluents, and combinations thereof. In some aspects, the additive is a pharma-ceutically acceptable additive or an acceptable food additive.

[0103] Although capsules are the preferred form of the compositions, the compositions and / or formulations of the present invention may be administered in any form, including, for example, one of a capsule, cachet, pill, tablet, powder, granules, pellets, beads, particles, lozenges, pastilles, liquid, elixir, syrup, tincture, suspension, emulsion, mouthwash, spray, drops, ointment, cream, gel, paste, transdermal patch, suppository, pessary, cream, gel, paste, foam, and combinations thereof. The compositions and / or formulations of the present invention may also include acceptable additives (e.g., solubilizers, enzyme inhibitors, anticoagulants, antifoaming agents, antioxidants, colorants, coolants, cryoprotectants, hydrogen bonding agents, flavoring agents, plasticizers, preservatives, sweeteners, thickeners, and one of a combination thereof) and / or acceptable carriers (e.g., excipients, lubricants, binders, disintegrants, diluents, bulking agents, solvents, suspending agents, solubilizing agents, isotonicity agents, buffering agents, soothing agents, amphipathic lipid delivery systems, and one of a combination thereof).

[0104] Although oral ingestion is the preferred method of administration of the compositions described herein, other routes and forms of administration may be possible using the methods and compositions described herein, including immediate release tablets or capsules (wherein the excipients disintegrate almost immediately upon coming into contact with saliva or gastric fluids), delayed release tablets or capsules, etc., sustained release formulations (wherein one or more of the components of the formulation are released in the stomach over an extended period of time), sublingual tablets, direct administration of the components via a catheter or feeding tube into the digestive tract, buccal delivery, and the like.

[0105] In certain implementations, the compositions and methods described herein are used to prevent, treat, or alleviate one or more symptoms of a respiratory illness. Non-limiting examples of such respiratory diseases include pulmonary hypertension, lung cancer, COVID-19, acute respiratory distress syndrome (ARDS), asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), pneumonia, interstitial lung disease, pulmonary fibrosis, acute lower respiratory tract infection, pulmonary edema, bronchitis, tracheobronchitis, acute lung injury (ALI), pulmonary sarcoidosis, bronchiectasis, asbestosis, beryllium poisoning, silicosis, anthracosis, histiocytosis X, pneumotitis, smoker's lung, bronchiolitis obliterans, lung scarring due to tuberculosis and pulmonary fibrosis, pneumoconiosis, traumatic lung injury, and pulmonary infections and pulmonary manifestations of connective tissue diseases, including systemic lupus erythematosus, rheumatoid arthritis, scleroderma, polymyositis, and dermatomyositis.

[0106] In certain implementations, the compositions and methods described herein are used to prevent, treat or alleviate one or more symptoms of diseases that cause hypoxia (e.g., altitude sickness, anemia, blood clots in the lungs (pulmonary embolism), congenital heart defects or heart diseases, medications that slow breathing rate (e.g., certain narcotics and anesthetics), lung inflammation due to toxic factors (e.g., nitrogen dioxide gas), scarring in the lungs (pulmonary fibrosis), and sleep apnea). EXAMPLES

[0107] Working Example The present disclosure is further illustrated by the following examples, which should not be construed as limiting. All references, patents, and published patent applications cited throughout this application, as well as figures, are hereby incorporated by reference in their entirety for all purposes.

[0108] Example 1: Oral administration of elemental magnesium and nitrate ions alleviates COVID-19 symptoms On October 21, 2000, a male subject aged 32 years began to show COVID-19 symptoms, including chest pain, fever, myalgia, cough, shortness of breath, and low oxygen saturation (between 90-92% during various measurements). Every 4 hours, the subject was administered two capsules on an empty stomach. One capsule contained 1200 mg potassium nitrate (KNO 3 ), 200 mg elemental magnesium, and 50 mg elemental zinc, and the other capsule contained 1000 mg citric acid (the contents of these capsules did not contain any binders, fillers or excipients and contained only the ingredients listed above).

[0109] Within 30 minutes of the first dose, the subject reported a significant reduction in shortness of breath, chest pain, and difficulty breathing. His oxygen saturation level also increased from 92% to 97%. The subject's oxygen saturation was monitored intermittently over a two-day period (Table 2). The subject's oxygen saturation level began to decrease within four hours, but upon taking another dose of the two capsules (one capsule with the elemental metals and nitrates, one capsule with citric acid), the subject's SpO2 returned to the normal range of 96%-100%. By the fourth day of taking the two capsules every four hours, the subject reported no symptoms of shortness of breath, chest pain, or breathing problems. In fact, he felt well enough to return to work, but remained in isolation due to local safety protocols. By the second day of taking the two capsules every four hours, the subject's oxygen saturation level had not decreased below normal. The subject later tested positive for Covid-19 infection. Table 2. Oxygen saturation tracking in subjects pre- and post-treatment [Table 2]

[0110] Example 2: Clinical trial in five adult COVID-19 patients clearly demonstrates efficacy of treatment An open-label case-control study conducted by the FSPE Applied Bioenergetics Lab (University of Novi Sad, Lovcenska 16, Novi Sad 21000, Serbia) evaluated the effect of a composition containing 1200 mg of potassium nitrate, 200 mg of elemental magnesium, and 50 mg of elemental zinc in one capsule, as well as 1000 mg of citric acid co-administered in another capsule, on blood oxygen saturation levels (SpO2) in COVID-19 patients. 2 ) and patient-reported outcomes.

[0111] Dyspnea and SpO 2 Five adult patients (3 males and 2 females, age 37.0±4.4 years) without COVID-19, with <95% pulmonary and cardiovascular disease, but no other pulmonary or cardiovascular conditions, were recruited for this study. The participants received the composition every 4 hours during a 48-hour monitoring period. No other treatments for improvement of oxygen saturation levels were administered during the trial. SpO 2 and patient-reported outcomes were assessed at baseline (before intervention) and at each 4-hour time point throughout the trial.

[0112] SpO 2 All participants experienced immediate improvement after administration of the composition (increase of 1-7%, mean increase 3.6±2.7 points; 95% confidence interval 0.3-7.0). 2 remained above baseline values ​​throughout the monitoring period, and values ​​persisted above the threshold (>92%) at each time point during the 48-hour period for all patients (see FIGS. 6A and 6B). If blood oxygen saturation levels fall below the 92% threshold, patients are advised to seek medical assistance. Thus, by keeping patients well above the threshold, stress on the health care system may be reduced.

[0113] The patients did not report any side effects of the intervention. In addition to improved blood oxygen saturation levels, one patient (female, 39 years old) reported reduced coughing, dyspnea, and chest pain. Another patient (male, 38 years old) reported reduced diarrhea. A third patient (female, 35 years old) reported reduced fatigue and headaches.

[0114] Example 3: Hydrogen gas is formed as a by-product of the reaction between elemental magnesium and citric acid To confirm that hydrogen gas is a by-product of combining the elemental metal with an acid, a teaspoon of elemental magnesium powder was added to a vial containing 100 ml of water saturated with citric acid. The air above the vial was flammable.

[0115] Example 4: Elemental magnesium and nitrate ions reduce symptoms of respiratory illness People with respiratory illness and SpO2 < 92% 2 Five subjects (male, 34-52 years old) with chronic respiratory tract infections were administered a composition containing 1200 mg potassium nitrate, 200 mg elemental magnesium, and 50 mg elemental zinc in one capsule, co-administered with another capsule containing 1000 mg citric acid. Their blood oxygen saturation levels were measured between 15 and 80 minutes after ingestion of the composition. Their symptoms related to respiratory ailments were also recorded before and after ingestion of the composition. Table 3 summarizes the results. Table 3. Improvement of respiratory symptoms after treatment

Table 3-1

Table 3-2

[0116] Example 5: Oral administration of elemental magnesium and potassium nitrate results in NO exhalation from the lungs Using the Niox Vero instrument, 1000 mg potassium nitrate (KNO 3 Ambient nitric oxide and pulmonary excretion of nitric oxide were measured in two subjects after ingestion of a composition having 100 mg elemental magnesium, 200 mg elemental magnesium, and 1 g citric acid co-administered in a separate capsule, which showed that ingestion of the composition resulted in immediate production of nitric oxide gas and increased pulmonary excretion of nitric oxide.

[0117] Example 6: Oral administration of elemental magnesium and nitrate improves blood oxygen levels and alleviates symptoms of post-COVID-19 lung injury and chronic hypoxia A male subject (40 years old, Brazilian) was diagnosed with COVID-19 on January 25th. He presented with symptoms of fatigue, tiredness, inability to exercise, work, inability to engage in sex, burnout, weakness, exhaustion, mental and physical exhaustion, lethargy, collapse, and tiredness. Even after he eventually tested negative for COVID-19, the symptoms persisted, and the subject's SpO2 levels (i.e., the percentage of oxygen in his blood) as measured by pulse oximeter were below 95% for several months after his infection and subsequent testing negative for the disease. The subject was eventually diagnosed with Acute Respiratory Distress Syndrome (ARDS).

[0118] On June 10, the subject was administered 1200 mg KNO 3 The subject took one capsule containing 200 mg elemental magnesium (mesh size 60-200), and 50 mg elemental zinc dust (mesh size 325) and a second capsule containing 1000 mg citric acid. Prior to taking the two capsules, his SpO2 level was 91 as measured by pulse oximeter. 50 minutes after taking the two capsules, his SpO2 level was 97 as measured by pulse oximeter. The subject took the composition every four hours for five days. He reported a reduction in all symptoms associated with COVID-19, which lasted for the duration of the treatment.

[0119] At the end of the initial five-day dosing protocol, the subject continued to take the composition once each morning to manage persistent COVID-19 symptoms. With just one maintenance dose of the described composition, the subject's SpO2 levels, as measured by pulse oximeter, never again fell below 95%, and all lingering symptoms of his original COVID-19 infection were alleviated.

[0120] Example 7: Elemental magnesium dust, when mixed with potassium nitrate in acid solution, produces NO and NO 2 Rapid gas production 200 mg elemental magnesium dust (mesh size 325 or finer; see Figures 5A-5C), 1200 mg KNO 3 A 100 ml glass beaker containing 100 mg of citric acid was mixed with 100 ml of distilled water. The beaker was placed in a sealed gas chamber (Bel-Art Secador Polystyrene Mini Desiccator Cabinet, 0.31 ft 3 ) and the resulting gaseous content was measured using a probe. 2 The sensor began to rise rapidly and stopped when it reached its maximum measurable capacity. Table 4 shows the NO and NO 2 Summarize the sensor results. Table 4. NO and NO over the course of the reaction. 2 Measurements

Table 4

[0121] The results were both surprising and unexpected. 60 seconds into the experiment, NO and NO 2 Both sensors reached a maximum of measurable capability at 250 ppm and 100 ppm, respectively. These surprising results indicate that magnesium mesh size is a critical factor for the safe use of the compositions, discoveries and inventions disclosed herein. With too small a particle size, the reaction proceeds too quickly and the NO and NO 2 Both gases rapidly reach non-therapeutic concentrations that are extremely dangerously toxic to humans.

[0122] According to the Occupational Safety and Health Administration (OSHA), at 2 ppm, NO 2 can trigger symptoms in people with asthma, and at 5 ppm it begins to damage the lungs, reducing NOx in your home and workplace. 2 The permissible exposure limit for 3 ), but as low as 0.1 ppm NO 2 Levels of NOx of 100 ppm have been shown to cause respiratory discomfort in vulnerable populations such as asthma patients. 2 can kill a human if exposed for about an hour. NO is therapeutic and safe at low concentrations, but is also downright toxic at concentrations of 100 ppm or higher. The invention disclosed herein enables, for the first time, a safe and effective method for therapeutic delivery of NO gas with little or no harmful side effects.

[0123] Example 8: Elemental zinc produces NO gas when mixed with potassium nitrate in acid solution An experiment similar to that described in Example 7 was performed with elemental zinc powder. Elemental zinc was found to be less reactive than elemental magnesium. The zinc powder reacted with potassium nitrate in citric acid solution to produce less NO and hydrogen than observed with magnesium over a 4-hour period.

[0124] Example 9: Elemental magnesium and nitrate improve blood oxygen levels and reduce coughing and weakness associated with respiratory illness, whereas an equal amount of nitrate alone has no effect A 58-year-old male subject presented with weakness, cough, and a blood oxygen saturation level (SpO 2 The subject was given a capsule containing only 1200 mg of potassium nitrate. After 15 minutes, the subject's SpO 2 The SpO2 in these subjects remained at 93% for up to 4 hours after administration of the potassium nitrate capsule. 2 showed no signs of augmentation or abatement of his other symptoms. Four hours after administration of the first capsule, the subject was administered a composition comprising a capsule containing 1200 mg potassium nitrate, 200 mg elemental magnesium, and 50 mg elemental zinc, and a separate capsule containing 1000 mg citric acid. Fifteen minutes after administration of this composition, the subject's SpO 2 increased to 97% and remained above 95% over 4 hours. The subject also reported experiencing a reduction in coughing and no longer felt weak.

[0125] Example 10: Elemental magnesium prevents methemoglobinemia induced by high sodium nitrite poisoning Sodium nitrite is known to be toxic in large amounts that can oxidize hemoglobin to methemoglobin (which cannot carry oxygen), an effect similar to methemoglobinemia induced by long-term NO gas treatment. Due to its toxicity, its use in therapeutics is limited to only antidotes used for cyanide poisoning. The calculated minimum lethal dose is 2.6 grams (Katabami et al., "Severe Methemoglobinemia due to Sodium Nitrite Poisoning", Case Reports in Emergency Medicine, 2016, Article ID 9013816, p. 3), although cases of severe methemoglobinemia have been reported at much lower doses, such as about 70 mg, in cases of geriatric patients with cardiovascular problems. Administration of 600 mg to adults for treatment of cyanide toxicity produced methemoglobin levels of 58% (van Heijst et al., "Therapeutic Problems in Cyanide Poisoning", Journal of Toxicology: Clinical Toxicology, 1987, 25(5): 383-398). Moderate to severe poisoning is associated with cyanosis (blueness of the skin), confusion, loss of consciousness, seizures, abnormal cardiac rhythms, and death. Due to the lack of observed cases of methemoglobinemia in subjects ingesting combinations of elemental metals and nitrate and / or nitrite ion sources or inhaling gases produced by said combinations in acidic solution, it was hypothesized that exposure to hydrogen gas and / or zinc or magnesium ions may prevent the development of methemoglobinemia. Methemoglobinemia occurs when methemoglobin is reduced to O 2 Since the blood cannot carry blood, higher methemoglobin levels result in lower oxygen saturation levels, and so can be monitored both directly by time-consuming blood tests, or indirectly by SpO2 measurements.

[0126] One of the authors fasted overnight and took 310 mg of NaNO 2 A capsule containing 1000 mg citric acid and one capsule containing 1000 mg citric acid were ingested with the intention of inducing methemoglobinemia while the other inventors monitored the test subject inventor's condition. After the first 15 minutes, the test subject inventor began to experience undesirable side effects including gastrointestinal distress, dizziness, brain fog, confusion, difficulty breathing, migraine headaches, abnormal palpitations, tachycardia with a peak of 240 beats per minute, and low SpO2 levels with a minimum reading of 91 approximately 25 minutes into the experiment. Table 5 summarizes the SpO2 levels and heart rate (HR) of the test subject inventor over the course of the experiment. SpO2 levels and heart rate readings were recorded. They can be found in the table below.

Table 5-1

Table 5-2

[0127] After a 48-hour washout period, the test subject inventor prepared three capsules, each containing 1000 mg elemental magnesium powder, and three other capsules, each containing 1000 mg citric acid. Elemental magnesium powder reacts violently with the acid in a highly exothermic reaction. It was therefore unknown whether the ingestion of such large amounts of elemental magnesium would be safe or even tolerable, and whether their reaction with a toxic dose of nitrite ion would be tolerable. Nevertheless, the test subject inventor simultaneously ingested a capsule containing 310 mg sodium nitrite and 1000 mg elemental magnesium, and two capsules, each containing 1000 mg citric acid (the amount of citric acid was doubled compared to the first dose in the first experiment, since some of the acid would be consumed by elemental magnesium). Thirty and sixty minutes later, the test subject inventor took another 1000mg elemental magnesium and 1000mg citric acid, each in capsule form. The inventor experienced none of the unwanted side effects of the first experiment. The only side effect noticed was dizziness when standing up, something the test subject inventor had experienced many times in previous experiments and easily identified as being related to low blood pressure. The test subject inventor's SpO2 level remained elevated compared to the first experiment and never dropped below the 95% threshold level. Table 6 summarizes the test subject inventor's SpO2 level and heart rate (HR) over the course of the second experiment.

Table 6

[0128] The test subject inventors felt completely fine for 90 minutes after the experiment. The test subjects' SpO2 levels were in the range of 95%-97%. Thus, administration of elemental magnesium prevented the development of methemoglobinemia induced by ingestion of sodium nitrite.

[0129] Example 11: Elemental magnesium and nitrate ions effectively treat asthma A female subject (71 years old, black American) diagnosed with asthma was given 1,200 mg KNO 3 One capsule containing 200 mg elemental magnesium (mesh size 60-200) and 50 mg elemental zinc, and a second capsule containing 1000 mg citric acid, was administered in the morning with a glass of cold water instead of using a preventative inhalant. The subject had tried various inhalants to treat her asthma with varying results, but upon oral administration of the capsules, the subject experienced immediate relief from her asthma symptoms. She also began to produce more phlegm and breathe better, which are signs of improvement in asthma patients. While receiving the treatment, the subject reported no side effects, including those associated with traditional asthma treatments (e.g., chest discomfort).

[0130] Example 12: Hydrogen gas prevents NO-induced methemoglobinemia During the course of developing the described method for generating NO into a more affordable, effective, and safe source of NO therapy, one of the inventors accidentally exposed himself to NO gas both chronically and acutely. The day after he exposed himself to high amounts of ambient NO (ambient NO >80 ppm), he began experiencing symptoms of methemoglobinemia, with pulmonary inflammation (as indicated by an SpO2 of 85%), dizziness, pulmonary pain, and weakness. Since the onset of symptoms, the inventor has been using H generated by reacting elemental magnesium and citric acid in a glass of water. 2 He also ingested 2000 mg elemental magnesium powder with water, which reacted with HCl in his stomach to produce H 2 In other experiments, the inventors showed that mild methemoglobinemia caused by inhalation of NO gas produced H 2 This was found to be reversed by administration of gas (as indicated by SpO2 returning to normal).

[0131] His condition and SpO2 worsened throughout the day, and later that evening he was admitted to the emergency room with a recorded SpO2 of 45%. The hospital verified that the inventor had NO-induced pulmonary inflammation via x-ray and CAT scan. Upon diagnosis, a blood sample was taken from the inventor to measure methemoglobin levels. To the surprise of the medical staff, methemoglobin was not detected even while the inventor had an SpO2 of 45%. The normal methemoglobin fraction is approximately 1%. He also never exhibited blue skin (cyanosis) during transport, which is associated with 3-15% methemoglobin levels. Thus, methemoglobin treatment (e.g., intravenous methylene blue) was not administered to the inventor.

[0132] Thus, hydrogen inhalation and ingestion (via the elemental metal form, in this case magnesium) treated and / or mitigated NO-induced methemoglobinemia. 2 Concentrations are in the range of approximately 530 ppb, which is ineffective in producing any protective effect in patients undergoing inhaled NO gas therapy, so a higher amount, at least 10 ppm, preferably 100 ppm or more, is needed for said protective effect, but the amount should be kept below 2000 ppm, preferably below 1500 ppm, to avoid water formation in the lungs.

[0133] Example 13: Nitric oxide is formed by reacting elemental magnesium and potassium nitrate in an acid solution An acid solution was created by dissolving 5g of citric acid in 100ml of warm water in a 1000ml beaker. Elemental magnesium (200mg) and potassium nitrate (1000mg) were added to the acid solution at the same time. According to a Niox instrument, which can measure ambient NO levels, FeNO was used to test whether NO gas formed from the addition of elemental magnesium and potassium nitrate to the acid solution. The NO level in the room prior to the experiment was 0. Immediately after adding elemental magnesium and potassium nitrate to the acid, the instrument recorded 200ppb NO. Since 200ppb is the detection limit of the instrument, more NO may have been generated.

[0134] Example 14: Elemental magnesium or elemental zinc is required to produce nitric oxide from potassium nitrate A flask containing 100 ml 0.1 M HCl was placed in a Bel-Art Secador Polystyrene Mini Desiccator Cabinet (0.31 cu. ft.). 3 The contents of one capsule containing 100 mg elemental magnesium, 200 mg elemental zinc, and 50 mg elemental zinc, and the contents of a second capsule containing 1000 mg citric acid were added to the flask. An NO sensor was placed in the desiccator cabinet. In 10 minutes, the NO level rose from 0 ppm to 6.4 ppm. Thus, theoretically, since an average stomach has a size of 1 liter, the amount of NO in the stomach from ingestion of the two capsules is 56 ppm.

[0135] Notably, a teaspoon of KNO 3 Addition of to 50 ml 25% HCl did not produce any measurable amount of NO gas.

[0136] Example 12: Size of elemental magnesium influences efficacy, safety, and side effect profile of administered compositions Multiple replicates of compositions having different mesh sizes of the elemental metal were prepared and tested in subjects to determine whether the mesh size of the elemental metal affects the benefits and / or side effects the subject experiences upon ingestion. Table 7 lists the formulations that were tested. Table 7. Formulations of elemental metals evaluated in the study

Table 7

[0137] The various preparations apparently demonstrated different effectiveness in alleviating respiratory ailments. In some cases, the subjects experienced side effects including gastrointestinal upset, diarrhea, nausea, and vomiting. Adverse effects were much more common with magnesium dust powder than with the other preparations.

[0138] Example 13: Various forms of elemental magnesium are mixed with potassium nitrate to form H 2 , NO, and NO2 Can produce gas Using 200 mg quantities of three forms (and sizes) of elemental magnesium (Figure 1), the total mass of 1200 mg KNO 3 and 1000mg citric acid powder was mixed with H 2 , NO, and NO 2 Gas production was compared. Immediately after adding 100 ml distilled water at room temperature, the beaker containing magnesium was placed in a Bel-Art Secador Polystyrene Mini Desiccator Cabinet (0.31 ft 3 At the start of the experiments with magnesium powder, granular magnesium, and magnesium beads, H 2 , NO, and NO 2 All the sensors were at zero.

[0139] Magnesium powder (60-200 mesh size) and 1200 mg KNO 3 Approximately 90 seconds after adding water to a beaker containing 1000 mg citric acid powder (see FIGS. 2A and 2B), the concentration of NO gas was 12.8 ppm, and NO 2 Gas is 0 ppm, H 2 The gas was 142 ppm. As the experiment continued, the NO and H 2 The gas concentration continued to increase. Two minutes after adding water to the powder, the NO gas concentration was 39.2 ppm and H 2 Gas is 435, NO 2 Gas was 0 ppm. NO vs. NO 2 This ratio is surprising. 2 It was unprecedented for NO gas to reach nearly 40 ppm with zero CO2. Five minutes after adding water to the powder, NO gas reached 49 ppm, while NO 2 Gas increased to 3.0 ppm. Hydrogen gas increased to over 1000 ppm (maximum detectable range of the sensor).

[0140] Granular magnesium (approximately 35 mesh size) and 1200 mg KNO 3 In the experiment with 1000 mg citric acid powder (see Figures 3A, 3B, and 3C), the NO gas, H gas, and 2 Gas, and NO 2 The concentrations of the gases were 3.8 ppm, 66 ppm, and 0 ppm, respectively. Five minutes after the addition of water, the sensor readings were 11.4 ppm for NO gas, 11.4 ppm for H 2 186 ppm for gas, and NO 2 Thus, the use of granular magnesium reduced NO and H gases in the same time frame when compared to magnesium powder. 2 The gas produced was much less and the NO produced was roughly four times less.

[0141] Magnesium beads (approximately 5 mm diameter) and 1200 mg KNO 3 In the experiment with 1000 mg citric acid powder (see Figure 1), at 1 minute 20 seconds into the experiment, neither NO gas nor NO 2 No gas was produced. Five minutes after adding water, the sensor reading for NO gas was 16.2 ppm, and NO 2 For gas it was 0 ppm and for hydrogen it was 337 ppm.

[0142] The inventors' experiments demonstrate the efficacy of the disclosed methods and compositions for 2 The simultaneous production of NO gas and NO gas 2 It has been shown to reduce or even eliminate gas production.

[0143] Example 14: Elemental magnesium and nitrate formulation effectively eradicates Helicobacter pylori Helicobacter pylori is a gram-negative, microaerophilic, spiral-shaped bacterium that is usually found in the stomach and upper small intestine. H. pylori prevalence ranges between 85% and 95% in developing countries and between 30% and 50% in developed countries. Symptoms of active infection include gastrointestinal pain (which is usually worse when the stomach is empty), nausea, loss of appetite, frequent eructations, abdominal bloating and involuntary weight loss, gastric ulcers, gastric bleeding, and irritable bowel syndrome. H. pylori is associated with many respiratory disorders, including chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, lung cancer, and tuberculosis. A common feature of H. pylori infection and chronic lung disease is chronic inflammation and an increased immune response. Eradication of H. pylori is difficult and requires the long-term administration of a combination of antibiotics (typically amoxicillin and clarithromycin) together with a PPI inhibitor (e.g. omeprazole) to avoid gastrointestinal side effects from antibiotic administration. A 50-year-old woman was diagnosed as positive for H. pylori and exhibited all the symptoms mentioned above. She had previously been prescribed a combination of amoxicillin (1000 mg twice per day), clarithromycin (500 mg twice per day) and omeprazole (20 mg twice per day) in a 30-day regimen, but H. pylori still tested positive after cessation of the above treatment. The inventor prescribed her a treatment consisting of one capsule with 10 mg sodium nitrite, 1000 mg potassium nitrate, and 200 mg elemental magnesium metal, and another separate capsule containing 500 mg citric acid and 500 mg gallic acid. She was advised to take the aforementioned capsule combination twice a day for 10 days. From the second day onwards, she reported relief of symptoms. Ten days later, she tested negative for H. pylori. Since then, many subjects who experienced chronic gastrointestinal pain have been taking 1200 mg KNO 3 Patients receiving a specific formulation of one capsule containing 200 mg elemental Mg, 50 mg elemental Zn, and one capsule containing 1000 mg citric acid taken twice daily reported elimination of gastrointestinal pain that existed prior to their infection.

[0144] Example 15: Hydrogen gas produced formulation It should also be noted that the inventors have realized that hydrogen, in high concentrations, can result in the formation of water, which, if absorbed for an extended period of time, can cause water to accumulate in the lungs of a subject and impede oxygen absorption from the lungs. This is why the inventors have used H for extended periods of time to counteract methemoglobinemia from NO. 2 This may explain the SpO2 he suffered when inhaling the gas. The relative humidity in the air and the H2O acquired from the formulation at an ambient temperature of 30°C may explain the SpO2 he suffered when inhaling the gas. 2 In a series of experiments comparing the concentration of H 2 It has been noted that for every 40 ppm increase in concentration, there is a 1% increase in relative humidity (the amount of water vapor present in the air expressed as a percentage of the amount required for saturation at the same temperature). 2 The results, with increasing concentration and increasing relative humidity, are shown in Table 8 below. Table 8. Effect of hydrogen gas on atmospheric humidity in a closed system

Table 8-1

Table 8-2

[0145] While the sensor limit was reached at 1000 ppm, the absence of any symptoms of water in the lungs (edema) in any of these experiments or in any of the subjects suggested that 1000 ppm H 2 Concentrations up to 1500 ppm H have been shown to be safe. 2 The concentration also exhibits significant H in the lungs of a subject inhaling gas produced from the composition. 2 It is assumed to be safe as there is no O formation.

[0146] Example 16: Significance of results in light of previous reports It has been shown that nitrate supplementation, in the form of sodium nitrate (Larsen FJ et al., Acta Physiol (Oxf). 2007 Sep;191(1):59-66) or beetroot juice (Bailey SJ et al., J Appl Physiol (1985). 2009 Oct;107(4):1144-55), can reduce oxygen consumption during exercise, but nitrate-rich beetroot juice supplementation failed to increase oxygen saturation levels (SpO2) in hypoxic conditions (lower than normal blood oxygen saturation, as in ARDS patients), failed to improve SpO2, and actually increased altitude sickness severity and the sense of effort during hypoxic exercise (Rossetti GMK et al., J Appl Physiol (1985). 2017 Oct 1;123(4):983-992). Furthermore, supplementation with potassium nitrate (KNO3), such as the form of nitrate utilized in our formulations to treat COVID-19 and other respiratory and circulatory diseases, resulted in a reduction in blood oxygen saturation (less than about 3%, a significant amount) in hypoxic conditions versus placebo (Schiffer TA et al., Respir Physiol Neurobiol. 2013 Jan 15;185(2):339-48). Thus, despite the hypothesis of Dr. Lundberg, Dr. Weitzberg, and their colleagues that nitrate increases SpO2 in hypoxia, KNO 3 Supplementation actually reduced SpO2 levels; in other studies, nitrate ions (as present in beetroot juice, for example) had no effect on SpO2.

[0147] A well-known drawback of NO gas therapy is the occurrence of methemoglobinemia (Weinberger B et al., Toxicol Sci. 2001 Jan;59(1):5-16). This is the oxidation of iron in hemoglobin, which makes the hemoglobin unable to carry oxygen. Methemoglobinemia can be diagnosed by a decrease in the subject's oxygen saturation, which can be measured with a pulse oximeter (SpO2). Other methemoglobinemia symptoms include skin discoloration (e.g., pale, gray, blue) and changes in blood color. Surprisingly, none of the subjects who took the formulation disclosed herein experienced methemoglobinemia (all of the subjects experienced an increase in SpO2 levels, whereas methemoglobinemia caused a decrease in SpO2 levels), and no abnormal changes in skin tone were noted. Thus, surprisingly, administration of the formula throughout the day did not cause methemoglobinemia.

[0148] Example 17: Elemental magnesium and nitrate ions effectively treat interstitial lung disease and associated chronic hypoxia A 77-year-old female subject suffered from interstitial lung disease with dyspnea and chronic hypoxia (SpO2 less than 95%). She also experienced chronic severe coughing attacks. She was advised not to take the citric acid capsules from the above formulation, as citric acid has been reported to exacerbate inflammation of the urinary tract due to cystitis.

[0149] She was given the above elemental metals and a nitrate ion preparation (600 mg KNO 3 A half dose of 100 mg elemental magnesium metal, 25 mg elemental zinc metal in a size 0 gelatin capsule was administered, which she swallowed with plenty of water on an empty stomach. Her SpO2 level was 94%. After 25 minutes, her SpO2 had increased to 98% while her pulse rate had dropped from 80 to 69, indicating a more efficient transport of oxygen and blood from the heart to the tissues. Over the course of 10 days, she continued to take the formulation multiple times per day, resulting in a sustained increase in SpO2 levels that remained in the normal range with a subsequent decrease in pulse rate. The subject also reported that her dyspnea was greatly reduced and that she was free of coughing fits with the treatment. The subject's blood pressure was monitored after each dose using a medical grade FDA approved device. With the initiation of the treatment, the subject's blood pressure decreased and remained reduced throughout her course of treatment. The patient experienced no negative side effects.

[0150] All headings are for the convenience of the reader and should not be used to limit the meaning of the material that follows the heading (unless so specified).

[0151] Unless otherwise defined, all technical and scientific terms in this specification have the same meaning as those commonly understood by those skilled in the art to which this invention belongs.Any method and material similar or equivalent to those described herein can be used in the practice or testing of this invention, but the preferred method and material are described herein.All publications, patents, and patent publications mentioned herein are incorporated by reference in their entirety for all purposes.

[0152] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

[0153] While the invention has been described in relation to specific embodiments thereof, it will be understood that further modifications are possible, and that this application is intended to include and cover any variations, uses, or adaptations of the invention generally in accordance with the principles of the invention, and such departures from the disclosure as come within known or customary practice within the art to which this invention pertains, and as may be applied to the essential features set forth hereinabove, and as fall within the scope of the appended claims.

Claims

1. A combination for increasing blood oxygen saturation levels (SpO2 levels) in a human subject, comprising at least one elemental metal and nitrate ions (NO3-), wherein the at least one elemental metal and the nitrate ions are orally co-administered to the human subject, and the at least one elemental metal is selected from the group consisting of elemental magnesium, elemental calcium, elemental zinc, elemental copper, elemental iron, elemental gold and elemental silver.

2. A combination for increasing blood oxygen saturation levels (SpO2 levels) in a human subject, comprising at least one elemental metal and nitrite ions (NO2-), wherein the at least one elemental metal and the nitrite ions are orally co-administered to the human subject, and the at least one elemental metal is selected from the group consisting of elemental magnesium, elemental copper, elemental zinc, elemental iron, elemental gold and elemental silver.

3. A combination for treating a condition selected from the group consisting of SARS-Cov-2 infection, post-coronavirus disease (COVID-19) hypoxia, acute respiratory distress syndrome (ARDS), post-ARDS hypoxia, pneumonia, chronic obstructive pulmonary disease (COPD), mesothelioma, anemia, asthma, pulmonary embolism, pulmonary collapse, congenital heart defect or disease, pulmonary edema, altitude sickness, interstitial lung disease, low respiratory rate, pulmonary inflammation, pulmonary fibrosis, sleep apnea, gastrointestinal infections, Heliobacter pylori infection, and respiratory infections, comprising at least one elemental metal and nitrate ion (NO3-), wherein the at least one elemental metal and the nitrate ion are orally co-administered to the human subject, and wherein the at least one elemental metal is selected from the group consisting of elemental magnesium, elemental copper, elemental zinc, elemental iron, elemental gold, and elemental silver.

4. A combination for treating a condition selected from the group consisting of SARS-Cov-2 infection, post-coronavirus disease (COVID-19) hypoxia, acute respiratory distress syndrome (ARDS), post-ARDS hypoxia, pneumonia, chronic obstructive pulmonary disease (COPD), mesothelioma, anemia, asthma, pulmonary embolism, pulmonary collapse, congenital heart defect or disease, pulmonary edema, altitude sickness, interstitial lung disease, low respiratory rate, pulmonary inflammation, pulmonary fibrosis, sleep apnea, gastrointestinal infections, Heliobacter pylori infection, and respiratory infections, comprising at least one elemental metal and nitrite ion (NO2-), wherein the at least one elemental metal and the nitrite ion are orally co-administered to the human subject, and wherein the at least one elemental metal is selected from the group consisting of elemental magnesium, elemental copper, elemental zinc, elemental iron, elemental gold, and elemental silver.

5. The combination according to any one of claims 1 to 4, further comprising a pharma- ceutically effective amount of an acid, wherein the at least one elemental metal, the source of nitrate anion (NO3-) and the acid are orally co-administered to the human subject.

6. 6. The combination according to claim 5, wherein the nitrate ions (NO 3 − ) and / or nitrite ions (NO 2 − ) are nitrates and / or nitrites, and the acid is citric acid.

7. 7. The combination of claim 6, wherein the nitrate and / or nitrite is potassium nitrate and / or potassium nitrite.

8. A combination described in any one of claims 1 or 2, characterized in that the NO inhalation therapy is administered to the human subject to increase blood oxygen saturation levels (SpO2 levels), and the human subject has an SpO2 level of less than about 95% or less than about 92%.

9. 9. The combination of claim 8, wherein the SpO2 level of the human subject is increased by at least about 1% within about 5 minutes to about 2.5 hours following the co-administration of the at least one elemental metal and the nitrate and / or nitrite.

10. 9. The combination of claim 8, wherein the SpO2 of the human subject is increased to at least about 94% within about 5 minutes to about 2.5 hours after the co-administration of the at least one elemental metal and the nitrate and / or nitrite ions.

11. 9. The combination of claim 8, wherein the SpO2 of the human subject is increased to at least about 95% within about 5 minutes to about 2.5 hours after the co-administration of the at least one elemental metal and the nitrate and / or nitrite ions.

12. The combination of claim 1 or 2, wherein the human subject has coronavirus disease (COVID-19).

13. The combination of claim 12, wherein the human subject has hypoxia after recovery from a SARS-CoV-2 infection.

14. The combination of claim 1 or 2, wherein the human subject has a viral respiratory infection.

15. The combination of claim 14, wherein the human subject is hypoxic.

16. The human subject may experience symptoms such as tissue damage, muscle pain, body pain, fatigue, sore throat, shortness of breath, difficulty breathing, chest pain, lung inflammation, cough, fever, loss of smell, loss of taste, sinus congestion, runny nose, decreased blood oxygen saturation, headache, gastrointestinal problems, nausea, vomiting, diarrhea, fatigue, inability to exercise, inability to work, inability to perform sexual activity, burnout, weakness, exhaustion, exhaustion, lethargy, collapse, tiredness, fatigue, worsening symptoms after physical or mental activity, difficulty thinking or concentrating, cough, stomach upset, vomiting, nausea, vomiting, diarrhea, vomiting, stomach upset ...

15. The combination of claim 14, wherein the human subject exhibits at least one symptom selected from the group consisting of pain, fast or pounding heartbeat, joint pain, tingling sensation, sleep problems, orthostatic dizziness, rash, mood swings, mood disorders, changes in menstrual cycle, hypertension, depression, increased heart rate, heart failure, and acute respiratory failure, and wherein said co-administration of said at least one elemental metal and said nitrate and / or nitrite ions alleviates said at least one symptom in said human subject.

17. The combination of claim 16, wherein the tissue damage is in the brain, heart, lungs and / or kidneys.

18. The combination of claim 1 or 3, wherein the combination comprises from about 1 mg to about 2000 mg of the at least one elemental metal and from about 30 mg to about 4000 mg of the nitrate ions.

19. The combination of claim 18, wherein the combination comprises elemental magnesium and / or elemental zinc.

20. The combination is Approximately 1200 mg potassium nitrate; Approximately 200 mg elemental magnesium; and Approximately 50 mg elemental zinc, The combination according to claim 1 or 3, comprising:

21. The combination is Approximately 1200 mg potassium nitrate; Approximately 200 mg elemental magnesium; Approximately 50 mg elemental zinc; and Approximately 1000mg citric acid Including, A combination according to claim 5.

22. The combination according to any one of claims 1 to 4, wherein the combination is provided in one tablet or more capsules.

23. 23. The combination according to claim 22, wherein the capsule has a size of 0 or less.

24. 20. The combination of claim 18, wherein said elemental magnesium has a mesh size of 60 to 200 and said elemental zinc metal has a mesh size of 325 or lower.

25. The combination of claim 2 or 4, wherein the combination comprises about 5 mg to about 300 mg of nitrite ions, about 10 mg to about 200 mg of nitrite ions, or about 30 mg and about 100 mg of nitrite ions.

26. 5. The combination of claim 2 or 4, wherein upon oral administration of said nitrite ions, said human subject does not develop methemoglobinemia.

27. ​​A combination described in any one of claims 1 to 4, further comprising at least one gastric acid secretion promoter, wherein the at least one gastric acid secretion promoter, the at least one elemental metal and the nitrate ion are orally co-administered to the human subject.

28. 28. The combination of claim 27, wherein the at least one gastric acid secretagogue is selected from the group consisting of caffeine, theophylline, theobromine, ethanol solutions, pentagastrin, and cholinergic agonists.

29. 29. The combination of claim 28, wherein the ethanol solution has between 2% and 14% ethanol.

30. 29. The combination of claim 28, wherein the cholinergic agonist is selected from acetylcholine and pilocarpine.

31. The combination of any one of claims 1 to 30, wherein the combination is provided in a sustained release formulation.

32. 1. A composition for human consumption comprising: at least one elemental metal in a mesh size equal to or greater than 35, wherein said elemental metal is at least one elemental metal selected from the group consisting of elemental magnesium, elemental calcium, elemental zinc, elemental copper, elemental iron, elemental gold and elemental silver; and Nitrate ion (NO 3 - ), nitrite ion (NO 2 - ), or both, A composition comprising:

33. 33. The composition of claim 32, wherein the elemental metal has a mesh size of 40 or greater.

34. 34. The composition of claim 33, wherein the nitrate ions and the nitrite ions are inorganic salts.

35. The composition comprises: from about 1 mg to about 800 mg of the at least one elemental metal; and About 30 mg to about 2000 mg of the nitrate ions and / or the nitrite ions 33. The composition of claim 32, comprising:

36. 36. The composition of any one of claims 32 to 35, wherein the at least one elemental metal is elemental magnesium of a mesh size between 60 and 200.

37. The composition of any one of claims 32 to 35, wherein the at least one elemental metal is elemental zinc metal having a mesh size of 325 or lower.

38. 36. The composition of any one of claims 32 to 35, wherein the composition is in a dosage form selected from capsules, cachets, pills, tablets, powders, granules, pellets, beads, particles, lozenges, and pastilles.

39. 40. The composition of claim 38, wherein said at least one elemental metal is packaged with said nitrate ions and / or said nitrite ions.

40. The composition of any one of claims 32 to 35, further comprising an acid.

41. 41. The composition of claim 40, wherein the composition comprises the acid in an amount of about 50 mg to about 20,000 mg.

42. 41. The composition of claim 40, wherein said acid is packaged separately from said at least one elemental metal and said nitrate ions and / or said nitrite ions.

43. 41. The composition of claim 40, wherein the at least one elemental metal, the nitrate ions, the nitrite ions, and the acid are in solid form.

44. The composition according to any one of claims 32 to 35, further comprising a gastric acid secretagogue.

45. 45. The composition of claim 44, wherein the gastric acid secretagogue is in an amount sufficient to reduce stomach pH.

46. 46. ​​The composition of any one of claims 33 to 45, wherein the elemental metal and the nitrate and / or nitrite ions are in a sustained release formulation.